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Patients with primary biliary cirrhosis (PBC) often have concurrent limited systemic sclerosis (SSc). Conversely, up to one-
fourth of SSc patients are positive for PBC-speciﬁc antimitochondrial antibodies (AMA). The mechanisms responsible for the
co-occurrence of these diseases are largely unknown. Genetic, epigenetic, environmental, and infectious factors appear to be
important for the pathogenesis of the disease, but the hierarchy of events are not well deﬁned. Patients with SSc and PBC have an
increased morbidity and mortality compared with the general population, but whether the presence of both diseases in an aﬀected
individual worsens the prognosis and/or outcome of either disease is not clear. Some case reports suggested that the presence of
SSc in PBC patents is associated with a more favorable prognosis of the liver disease, whereas others report an increased mortality
in patients with PBC and SSc compared to patients with PBC alone. This paper discusses the features of patients with PBC-
associated SSc. Our aims are to clarify some of the pathogenetic, diagnostic, and clinical challenges that are currently faced in the
routine management of these patients. We also intend to provide some practical hints for practitioners that will assist in the early
identiﬁcation of patients with PBC-associated SSc.
1.Introduction
1.1. Primary Biliary Cirrhosis. Primary biliary cirrhosis
(PBC) is a chronic cholestatic liver disease characterized by
immune-mediated chronic nonsuppurative cholangitis that
mainly aﬀects interlobular and septal bile ducts [1–3]. PBC
is a rare disease with prevalence ranging from 28 to 402 per
million [4], which is highly variable based on geographical
location. PBC primarily aﬀects middle aged women [5].
Several reports indicate that the incidence and prevalence of
PBC is increasing in the UK, USA, Finland, and Australia [4–
7]. PBC often occurs in association with other autoimmune
conditions [1–3]. The serological hallmark of PBC is the
presence of high-titre serum antimitochondrial autoanti-
bodies (AMA), usually existing in 90–95% of patients with
PBC [1–3, 8–16]. The presence of AMA in asymptomatic
patients is usually indicative of eventual PBC development
[17]. These autoantibodies speciﬁcally recognize lipoylated
domainswithincomponentsofthe2-oxoaciddehydrogenase
family of enzymes, particularly the E2 component of the
pyruvate dehydrogenase complex, located within the inner
mitochondrial membrane [1–3, 8–12]. Indirect immunoﬂu-
orescence using rodent liver, kidney, and stomach sections
as substrate is still the most widely used screening assay
for AMA in the routine setting [18]. Other techniques such
as immunoblotting and ELISA have a higher sensitivity,
and the use of cloned mitochondrial antigens and bead
assay testing systems allows for the identiﬁcation of AMA
in the sera of patients previously deﬁned as AMA negative
[19]. Additionally, PBC-speciﬁc antinuclear autoantibodies2 International Journal of Rheumatology
(ANAs) can be observed in 30% of patients presenting with
multiple nuclear dot (antibodies against Sp100) or nuclear
membrane staining patterns (antibodies against gp210) [9,
10, 12, 14, 20], which are preferentially identiﬁed using HEp-
2 cells as substrate [21] .T h ea u t o i m m u n en a t u r eo fP B Ci s
supported by a plethora of experimental and clinical data,
such as the presence of autoreactive T cells and serum auto-
antibodies in patients with PBC [8, 15, 22–31].
The aetiology of PBC remains unknown, although evi-
dence suggests a role for both genetic susceptibility and envi-
ronmental factors that remain to be characterized. In fact,
a number of chemicals and infectious agents have been
proposed to induce the disease in predisposed individuals
[22–27, 30, 32–38]. At presentation, patients with PBC
may have nonspeciﬁc symptoms such as pruritus and
fatigue while jaundice is less frequently seen [1–3]. Portal
hypertension and its complications may also develop in
patients with early, pre-cirrhotic PBC [1–3]. However, the
majority of PBC patients are asymptomatic and diagnosed
incidentally during the diagnostic workup or treatment for
other conditions [39, 40]. Currently, a deﬁnite diagnosis of
PBC is made on a combination of abnormal serum enzymes
indicating cholestasis (i.e., elevated alkaline phosphatase for
atleastsixmonths),thepresenceofserumAMA(titre>1:40
by indirect immunoﬂuorescence), and characteristic liver
histology with ﬂorid bile duct lesions [1–3, 18]. A probable
diagnosis is made when two out of these three criteria
are present. Serum AMAs (or disease-speciﬁc antinuclear
antibodies) may precede disease onset by several years, and
many individuals found positive for these autoantibodies in
the absence of other criteria eventually develop PBC [17].
PBC has a progressive course which may extend over
many decades, with greatly variable progression rates among
patients. The end of this progression is characterised by
cirrhosis, liver failure. However, the patterns of clinical
disease and natural history have changed signiﬁcantly in
the last two decades after the introduction of medical
treatment with ursodeoxycholic acid (UDCA). When UDCA
is administered in early PBC at adequate doses (13–
15mg/kg/day), the progression of the disease is altered,
with many patients having a normal life expectancy without
additional therapeutic measures [41].
Concomitant autoimmune diseases are often found in
patients with PBC. PBC is found in patients with systemic
sclerosis (SSc). Also, SSc is one of the most frequent autoim-
mune rheumatological conditions associated with PBC. This
paper discusses the major characteristics of patients with
PBC and SSc, and provides clues related to their immuno-
pathogenic link (Table 1).
2.PBC-SSc
2.1. Epidemiology. PBC has been considered as the most
common liver disorder in patients with systemic sclerosis
(SSc) [42]. This association was ﬁrst described to co-occur
by Milbradt in 1934, and it has been noted historically in
several case reports. One such case from 1964 reports two
patients with SSc and possible (but unconﬁrmed) PBC [43].
Murray-Lyon et al. report two cases of SSc and PBC [44].
The ﬁrst case was that of a 64-year-old female with Raynauds
and scleroderma of the right hand and arm, who was
found to have hepatosplenomegaly [44]. She was positive for
AMA, and a liver biopsy conﬁrmed the diagnosis of PBC
[44]. The second case was similar, with AMA positivity and
PBC conﬁrmed on liver biopsy [44]. Despite several similar
reports over the years, liver disease has not been considered a
signiﬁcant feature of scleroderma, and a higher prevalence
of liver disease was found in the control populations of
several large studies [45, 46]. The association of lcSSc and
PBC was ﬁrst described in 1970 with two cases of PBC and
limited scleroderma [44]. A further six cases were reported
by Reynolds et al. [47], and several other case reports have
found an association between lcSSc and PBC. The ﬁrst case
reporting an association of PBC and scleroderma, without
features of lcSSc, was described in 1972 [48]. The prevalence
of clinically evident PBC among patients with SSc was
recentlyreportedtobe2.5%inaregistryof1700SScpatients
[49] and 2% in a series of 817 patients with SSc [50]. On
the other hand, the prevalence of SSc in patients with PBC is
estimated to be around 8%, as demonstrated by two studies
comprising large cohorts of patients with PBC [49, 51].
However, case reports [44, 47, 48, 52–63] and some series
reported a wider range of prevalence (3–50%) of SSc, mostly
lcSSc, in PBC patients [42, 49, 51, 55, 61, 64, 65].
Large epidemiological studies on PBC note a minority
of patients who also have SSc (scleroderma). A large French
study found scleroderma in 1% of a cohort of PBC patients,
although1%oftheirﬁrst-degreerelativesand1%ofcontrols
were also noted to have scleroderma [66]. One of the most
comprehensive epidemiological studies by Gershwin and
colleagues found that 2% of PBC patients and 1% of their
ﬁrst-degree relatives had scleroderma, compared to none
of the controls [39]. First-degree relatives with scleroderma
were more often sisters, followed by daughters of PBC
patients [39, 67]. Twin studies in both conditions are scarce.
One twin study for SSc found a low concordance of 4.2%
among monozygotic (MZ) twins, compared to 5.6% in
dizygotic (DZ) twins [68]. Interestingly, there was a 90%
concordance for ANA among MZ twins, compared to only
40% among DZ [68]. A higher concordance of 63% among
MZ twins was found in the only comprehensive twin study
in PBC [69]. Although both twin studies note co-existing
autoimmune disease, which was often the same condition in
the twin, none have noted SSc in twins with PBC or PBC in
twins with SSc.
2.2.Immunopathogenesis. Despitethescarcityofcasereports
and large-scale studies, the association of PBC and sclero-
derma seems to be more than coincidental and suggests that
these two diseases might have a common autoimmune basis.
However, the autoimmune mechanisms behind the PBC-SSc
associationarestillnotfullyunderstood.Ithasbeenreported
that this patient group has clonally expanded CD8(+) T cells
expressing one T-cell receptor beta-chain variable region,
TCRBV3, which may be involved in the disease pathogenesis
[70]. Genetic, epigenetic, environmental, and infectiousInternational Journal of Rheumatology 3
Table 1: Features demographic, immunological and genetic features of primary biliary cirrhosis (PBC) and systemic sclerosis (SSc).
PBC SSc
Prevalence (highly variable geographically) 28–402/million 50–200/million
Incidence (highly variable geographically) 2.3–27/million 0.6–122/million
Male to female ratio 1:8 1:1.5–12 (highly variable geographically)
Peak frequency age 53 years 45–64 years
Autoantibodies AMA, ANA
Limited disease: ACA, anti-Th/To,
anti-U1-RNP
Diﬀuse disease:T O P O ,a n t i - R N Ap o l y m e r a s e
III, anti-U3-RNP
Genes (positive associations)
HLA: DRB1, DQA1, DQB1, DQA2
HLA:H L A - D R B 1 ∗1104, DQA1∗0501,
DQB1∗0301, HLA-DRB1∗0804, DQA1∗0501,
DQB1∗0301
Non-HLA: IRF5, STAT4, SPIB,
IKZF3-ORMDL3, IL12A, IL12RB, MMEL1,
DENND1B, CD80, IL7, CXCR5,
TNFRSF1A, CLEC16A, NKFB1
Non-HLA: STAT4, IRF5, BANK1, TNSF4,
TBX21, IL-23R, and C8orf13-BLK
AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; ACA, anti-centromere antibody.
factors appear to be important for the induction of the
underlying autoimmune pathology, but the hierarchy of
events and the close interplay of these factors are not well
deﬁned.
The association between PBC and SSc has been largely
based on reports indicating the presence of autoantibodies
related to SSc in patients with PBC and vice versa.A u t o a n -
tibodies which characterize limited cutaneous SSc (lcSSC)
include anti-centromere antibodies (ACA), anti-Th/To, anti-
U1-RNP, and PM/Scl. Diﬀuse cutaneous SSc (dcSSc) is
characterized by anti-Scl 70 antibody (anti-topoisomerase I
antibody, TOPO), anti-RNA polymerase III, and anti-U3-
RNP [71]. Severe lung disease is the hallmark of anti-TOPO-
positive dcSSC patients. DcSSc patients with anti-RNA poly-
merase III have the most severe skin disease and the highest
frequencyofrenalcrisis.Patientswiththenucleolarantibody
anti-U3-RNP have dcSSc with multiorgan involvement [71].
The autoimmune basis of association between PBC
and SSc was ﬁrst established by the presence of AMA in
approximately 5% of patients with scleroderma and ACA
in one-quarter of patients with PBC [55]. A positive ACA
is reported in 9–30% of PBC patients [59, 72–75] and in
22–25% of all SSc patients, almost all of which have lcSSc.
Conversely, up to 25% of SSc patients are AMA positive, but
the high prevalence rates of AMA are probably secondary to
referral bias and overestimate the frequency of AMA in SSc
[76–79]. Another interesting point which needs attention is
that of studies reporting a relatively high prevalence of AMA
negative PBC in patients with SSc or other autoimmune
diseases[51,80]theautoantibodyproﬁleofSScpatientswith
AMA-negative PBC may require the use of highly sensitive
immunoassays for the detection of AMA. It has been shown
that such assays are able to detect AMA in serum samples
from SSc patients characterized as AMA negative by indirect
immunoﬂuorescence, and this may be the case for other
PBC-speciﬁc autoantibodies, such as ANA speciﬁc for sp100
[11, 12, 50].
ACA positivity is greater in PBC-SSc than in either
disease in isolation, but there is no cross-reactivity between
mitochondrial and centromere antigens [81]. Because ACA
have been detected not only in SSc but also in other
autoimmune diseases [82–85] including PBC [72, 86], the
clinical signiﬁcance of ACA in PBC has been the focus
of ongoing research. Three major centromere antigens
have been recognized: centromere protein A (CENP-A,
18kD polypeptide), centromere protein B (CENP-B, 80kD
polypeptide), and centromere protein C (CENP-C, 140kD
polypeptide). One study attempted to identify the major
epitope of ACA in sera obtained from patients with PBC
and to classify the correlation between the presence of ACA
epitopes and the clinical features in patients with PBC
[87]. The serological results obtained were compared with
clinicalfeaturesoflcSScinPBC.Forty-onepatientswithPBC
were studied: 10 out of 16 (63%) patients with ACA (all
anti-CENP A) had one or more lcSSc feature. The higher
incidence of Raynaud’s phenomenon seen in ACA-positive
patients with PBC than that in ACA-negative patients with
PBC suggested a close association of the presence of ACA
withclinicalfeaturesoflcSScinpatientswithPBC[87].From
the results of this study, it was proposed that there is a subset
of PBC patients with scleroderma who are ACA positive and
diﬀer from both ACA-negative PBC-SSc and ACA-negative
PBC non-SSc patients, based on their clinical features and
ACA epitope reactivity [87].
Over the past two years, a tremendous amount of
data has come available as to the genetics underlying
PBC and SSc. In regards to SSc, several HLA and
non-HLA regions have been identiﬁed [88], with HLA
regions showing variability among ethnic groups. Positive
HLA associations in whites and Hispanics include HLA-
DRB1∗1104, DQA1∗0501, DQB1∗0301 [89]. Negative asso-
ciations in those groups included DRB1∗0701, DQA1∗0201,
DQB1∗0202, and DRB1∗1501 [89]. Positive HLA associ-
ations in African Americans included HLA-DRB1∗0804,4 International Journal of Rheumatology
DQA1∗0501, and DQB1∗0301 [89]. That study also noted
that ACA positivity was closely associated with HLA-
DQB1∗0501 [89], and another study found an association
between TOPO positivity and HLA-DRB1∗1104 [90]. A
smaller study of a Spanish cohort showed similar HLA
ﬁndings to those noted above [90] .S e v e r a ln o n - H L Ar e gi o n s
have also been identiﬁed in SSc. These include STAT4
[88, 91–94], IRF5 [88, 95, 96], BANK1 [97, 98], TNSF4
[99], TBX21 [92], IL-23R [100], and C8orf13-BLK [101]
among others [88]. As with SSc, several HLA and non-
HLA regions have been identiﬁed in PBC. HLA regions
include DRB1, DQA1, DQB1, and DQA2 [102, 103]. Non-
HLA regions include IRF5, STAT4, SPIB, IKZF3-ORMDL3,
IL12A, IL12RB, MMEL1, DENND1B, CD80, IL7, CXCR5,
TNFRSF1A,CLEC16A,andNKFB1[104–106].Interestingly,
PBC and SSc have several genes in common: HLA-DRB1,
DQA1, DQB1, IRF5, and STAT4, although it should be
noted that DR11, which is positively associated with SSc, is
considered protective in PBC [88, 105].
Infectious agents have been implicated in the pathogene-
sis of both SSc and PBC. A number of organisms, such as E.
coli, have been strongly associated with PBC [22, 107, 108],
but not with SSc. Helicobacter pylori and Chlamydia have
been implicated in both conditions [109–119]; however,
some studies indicate the Chlamydia is not involved [72, 120,
121]. It is possible that certain infectious organisms con-
tributes to the development of PBC or SSc in isolation and
that other organisms induce the disease in both conditions.
2.3. Screening and Diagnosis of PBC in SSc Patients and
Vice Versa. Given the overlap between PBC with SSc and
vice versa, including ACA positivity in PBC patients and
AMA positivity in SSc patients, the major challenge remains
to clarify which screening method would be best for early
diagnosis of the associated conditions.
Firstly, routine screening for PBC-speciﬁc antibodies in
patients with SSc needs to be further reﬁned. Recently,
Norman et al. investigated the presence of antibodies against
PBC disease-speciﬁc mitochondrial antigens and antibodies
against the sp100 nuclear body antigen in 52 patients with
SSc, by using two commercially available ELISAs [79]. In
that study, 13% of cases were positive for AMA and 2%
for ANA (anti-sp100), and one patient (2%) was diagnosed
with symptomatic PBC [79]. These ﬁgures were reproduced
by Mytilinaiou et al., who conﬁrmed 13.5% positive results
with ELISA testing for antibodies against PBC disease-
speciﬁc mitochondrial antigens in 37 SSc patients [78].
However, this was not conﬁrmed with the conventional indi-
rect immunoﬂuorescence based on unﬁxed rodent kidney,
liver, stomach tissue sections, or HEp-2 cells as antigenic
substrates, and none of the ELISA-positive patients showed
features of PBC [78]. It remains to be clariﬁed whether
ELISA testing is less speciﬁc with false positive results or that
it simply represents a more sensitive method with respect
to indirect immunoﬂuorescence, which should currently
remain the technique of choice.
Nevertheless, the presence of AMA can precede clinical
symptoms of PBC. Indeed, Mitchison et al. and Metcalf et al.
showed that the vast majority of AMA-positive subjects have
typical histological features of PBC despite being asymp-
tomatic with normal biochemistry [17, 122]. Furthermore,
the study by Prince et al. suggested that 36% of initially
asymptomatic PBC patients would become symptomatic
within a median time of 5 years [123]. Thus, AMA-positive
SSc cases require immediate attention and close, long-term
monitoring for early detection of symptoms, signs, and
liver biochemistry suggestive of chronic cholestatic liver
disease. Routine followup of AMA-positive SSc patients
should include liver tests (alanine aminotransferase, aspar-
tate aminotransferase, γ-glutamyl transpeptidase, alkaline
phosphatase, albumin, bilirubin, international normalized
ratio), thyroid function, and possibly an annual ultrasound
abdominal scan. Transient elastography of the liver has
been used to assess biliary ﬁbrosis in patients with PBC
[124]. This test is emerging as a useful screening tool
to detect undiagnosed chronic liver disease in apparently
healthy subjects [125]. Whether patients with SSc, who are
tested positive for PBC-speciﬁc AMA, need regular checks
with transient elastography or more common tests, such as
liver ultrasound, needs to be evaluated in large prospective
multicentre studies. Currently, there is no evidence that
either of these would be of value. Figure 1 illustrates the
diagnostic and screening algorithm for PBC in SSc patients.
Screening PBC patients for ACA is not mandatory but
can be considered, especially in the presence of disease-
related symptomatology. Nakamura et al. reported that, in
PBC patients, ACA positivity was signiﬁcantly associated
with more severe ductular pathology on liver histology
and was a signiﬁcant risk factor for the development of
portal hypertension [126]. In another study, ACA-positive
PBC patients without clinical features of SSc were shown
to have similar symptoms and signs at diagnosis [49].
Although ACA positivity is not pathognomic of SSc, it is
associated with an increased risk of developing connective
tissue disease [127]. One review [128] reported a sensitivity
of 32% (17–56%) for SSc and 57% (32–96%) for lcSSc
and speciﬁcity of at least 93%, while ACA positivity was
present in 5% of patients with other connective tissue dis-
eases and less than 1% of disease-free controls. Since
ACA could be predictive of rheumatic disorders, it has
been suggested that an assessment of PBC patients should
always include screening for SSc-related symptoms, such
as Raynaud’s phenomenon and CREST-related symptoms
(calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, and telangiectasia) [129]. The use of nail-
fold videocapillaroscopy in patients suspected of having
connective tissue disease may be a useful indicator. Some
evidence suggests that this assessment can be useful for the
diagnostic and/or clinical management of patients with PBC
and suspected SSc. Experimental and clinical observation
suggests that patients with PBC have endothelial dysfunction
[130]. In an interesting study, nailfold videocapillaroscopy
abnormalities were found in 91% of patients with PBC,
and capillary alterations characteristic of SSc were found
in 54% [131]. Eleven out of the 22 PBC patients (50%)
had extrahepatic signs of connective tissue disease with
most being related to SSc, while patients with other types
of chronic liver disease did not present with rheumaticInternational Journal of Rheumatology 5
Systemic sclerosis (SSc)
History and physical examination
AMA
No symptoms or signs of
cholestatic chronic liver disease
and
normal liver function tests
Surveillance
Negative
Abnormal
Surveillance
Normal
AMA,
transient elastography
Positive
Negative Positive
Refer to hepatologists
Symptoms or signs of
cholestatic chronic liver disease
and/or
abnormal liver function tests
Probable PBC Reconsider diagnosis
Regular checks of abnormal liver
transient elastography
function tests and review
of abdominal ultrasound and
abdominal ultrasound,
Figure 1: A proposed algorithm for the screening and diagnosis of primary biliary cirrhosis (PBC) in patients with established systemic
sclerosis (SSc).
manifestations [131]. In PBC patients, there was a signiﬁcant
association between SSc capillary pattern and rheumatic
manifestations. The high prevalence of nailfold capillary
abnormalities characteristic of SSc in patients with PBC, and
correlation with sclerodermal manifestations, suggests that
this capillaroscopic ﬁnding could be a useful indicator to
investigate rheumatic manifestations in these patients [131].
Further clinical assessment of organ involvement (especially
lung by spirometry) in association with evaluation of
pulmonary artery pressure on echocardiography should be
consideredinPBCpatientswithadeﬁnitediagnosisofSSc.A
proposed diagnostic and screening algorithm for SSc in PBC
patients is presented in Figure 2.
2.4. Clinical Presentation and Prognosis. In approximately
60% of the cases, the clinical presentation of SSc precedes
that of PBC. The demographics of the disease in patients
with overlapping features are not well deﬁned. For example,
it is not clear whether in the PBC-SSc group the diagnosis
of PBC occurs at a lower age than that in patients with PBC
alone. In a study of 43 PBC-SSc patients, the median age at
diagnosis of PBC made after SSc diagnosis was lower (46.1
years) than in PBC diagnosed before SSc (51.1 years). This
waslowerthanthediagnosisinPBCalone,withamedianage
of 53.2 years at diagnosis [49]. The diﬀerent age at diagnosis
in the PBC-SSc patients, compared to patients with PBC
alone, was probably due to the eﬀect of lead time bias (i.e.,
screening for PBC in SSc patients and thus early diagnosis of
asymptomatic PBC, since 56% presented with SSc alone).
PBC-SSc patients were reported to have a higher inci-
dence of a ﬁrst episode of spontaneous bacterial peritonitis
and septicaemia during followup with respect to patients
with PBC alone. This is likely due to an increased risk of
infection due to immune abnormalities and organ system
manifestations associated with SSc [132].
Both SSc and PBC are associated with increased mor-
bidity and mortality compared with the general population
[123, 133–139]. Among the disease-related causes of mortal-
ity in SSc patients, pulmonary ﬁbrosis, pulmonary arterial
hypertension, and cardiac causes (mainly heart failure and
arrhythmias) are reported to account for the majority
of deaths. The most frequent non-SSc-related causes of
death are infections, malignancies, and cardiovascular causes
[140]. In PBC patients, liver-related causes account for
roughly 50% of deaths, whereas cardio- and cerebrovascular
causes together with malignancies are responsible for the
non-liver-related deaths [139, 141]. Some case reports [62,
142] suggest that PBC in association with SSc is associated
with a more favourable prognosis than PBC alone, whereas
others reported increased mortality due to SSc [143]. In
the study which included 43 PBC-SSc patients, liver disease
had a slower progression in PBC-SSc compared to matched
patients with PBC alone. A lower rate of liver transplan-
tation and liver-related deaths was demonstrated in PBC-
SSc patients compared to patients with PBC alone, and
these diﬀerences were not due to earlier SSc-related deaths
[49]. However, the improvement in liver-related survival
in the PBC-SSc cohort was outweighed by an increase in6 International Journal of Rheumatology
Primary biliary cirrhosis (PBC)
History and physical examination
ACA
No symptoms or signs of SSc
Positive Negative
Positive
Positive
Echocardiography
Surveillance
Surveillance
Negative
Negative
Symptoms or signs of SSc
Refer to rheumatologist
Reconsider diagnosis Diagnosis of SSc
Nailfold videocapillaroscopy
ACA, TOPO, ANA
spirometry
nailfold videocapillaroscopy,
echocardiography,
Figure 2: A proposed algorithm for the screening and diagnosis of systemic sclerosis (SSc) in patients with established primary biliary
cirrhosis (PBC).
non-liver-related deaths due to SSc, and, thus, overall
survivalwasnotdiﬀerentinPBC-SScpatientsandthosewith
PBC alone [49]. These data emphasize the importance of
comorbidity in PBC. More data on the outcome of patients
with PBC and PBC with SSc are needed. If patients with
PBC and SSc have a lower rate of liver transplantation
and liver-related deaths compared to patients with PBC
alone [49], it would be expected that patients with PBC
and SSc-related ACA would also have better prognosis than
their seronegative counterparts, but this does not appear
to be the case [126]. It may be that the outcome of
patients with ACA-positive PBC, who do not have SSc-
related symptoms, diﬀers from that of ACA-positive SSc and
PBC overlap.
Prince and colleagues observed an increase in non-
hepatic deaths in asymptomatic PBC, even with a reduced
liver-related mortality, in comparison with symptomatic
PBC [123]. Since the causes of death in PBC-SSc patients
are mainly due to SSc and not to liver disease, these patients
may need diﬀerent prognostic models in order to better
predict their liver-related survival. Prognostic models for
PBC alone may not be applicable for PBC associated with
SSc or for other associated autoimmune diseases to assess
the risk of liver-related mortality and the need for liver
transplantation.
2.5.Therapy. AllPBCpatientswithabnormalliverbiochem-
istry should be considered for speciﬁc therapy. UDCA at the
dose of 13–15mg/kg/day on a long-term basis is currently
considered the mainstay of therapy for PBC [18]. In the early
stagesofPBC,UDCAprotectsinjuredcholangiocytesagainst
the toxic eﬀects of bile acids. In later stages of the disease,
UDCA stimulates impaired hepatocellular secretion, mainly
by posttranscriptional mechanisms [144]. In addition, stim-
ulation of ductular alkaline choleresis and inhibition of bile
acid-induced hepatocyte and cholangiocyte apoptosis are
includedamongthebeneﬁcialeﬀectsofUDCAinPBC[144].
UDCA has been demonstrated to markedly decrease serum
bilirubin, alkaline phosphatase, γ-glutamyl transpeptidase,
cholesterol, and immunoglobulin M levels and to ameliorate
histological features in patients with PBC in comparison
to placebo treatment [145–149]. However, no signiﬁcant
eﬀects on fatigue or pruritus were observed in these large
trials nor were eﬀects on survival [150]. Favorable long-
term eﬀects of UDCA are observed in patients with early
diseaseandinthosewithagoodbiochemicalresponse,which
should be assessed after one year from start of treatment
[18]. A good biochemical response after one year of UDCA
treatmentiscurrentlydeﬁnedbyaserumbilirubin≤1mg/dL
(17μmol/L), alkaline phosphatase ≤3x ULN, and aspartate
aminotransferase ≤3x ULN, according to the “Paris criteria”
[151]. The “Barcelona criteria” indicates a good response
with a 40% decrease or normalization of serum alkaline
phosphatase [152].
Whether treatment with UDCA has an eﬀect on the
symptoms and the outcome of SSc remains poorly under-
stood. Prospective studies of patients with PBC-associated
SSc who are followed-up for many years under UDCA
treatment are needed to address this issue.International Journal of Rheumatology 7
The treatment of SSc is complex and may include drugs
with hepatotoxic potential. For example, the use of endothe-
lin-1 receptor antagonist bosentan, which is the treatment of
choice for SSc-related pulmonary artery hypertension, has
been associated with increased risk of elevated aminotrans-
ferases [153–155]. When PBC is present, the management of
SSc patients is more challenging, as this autoimmune liver
disease may pose further risk factors or unwanted complica-
tions. Whichever therapy is to be implemented, it is recom-
mended that collaboration takes place between specialists
responsible for the care of these patients.
3. Conclusions
The association of SSc and PBC is a rare but intriguing
autoimmune syndrome which challenges the expertise and
interests of hepatologists and rheumatologists in terms of
early diagnosis and shared management. A major eﬀort
should be made for continuing collaborative research in this
ﬁeld aimed at achieving a better understanding of the im-
munopathogenesis, genetic background, and demographic
featuresofpatientsathigherriskofdevelopingtheassociated
conditions. These ﬁndings may also contribute to the devel-
opmentofspeciﬁcprotocolsforpreventingdevelopmentand
evolution of the two associated diseases.
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